Patient characteristics (N = 110)

Characteristics
Sex
    Male85 (77%)
    Female25 (23%)
Age (range) (mean) (median) (yr)30–87, 59, 58
Primary tumor location
    Oropharynx51 (46%)
    Oral cavity19 (17%)
    Larynx19 (17%)
    Hypopharynx6 (6%)
    Nasopharynx6 (6%)
    Unknown primary5 (5%)
    Paranasal sinuses/nasal cavity4 (3%)
HPV status (oropharynx) (n = 51)
    Positive35 (69%)
    Negative8 (15.5%)
    Unknown8 (15.5%)
Tumor stage (AJCC Cancer Staging Manual, 7th ed)
    T-stage
        T05 (5%)
        T122 (20%)
        T230 (27%)
        T325 (23%)
        T428 (25%)
    N-stage
        N028 (25%)
        N117 (15%)
        N261 (57%)
        N34 (3%)
    M-stage
        M0107 (97%)
        M13 (3%)
        MX0 (0%)
    TNM stage
        I1 (1%)
        II9 (8%)
        III22 (20%)
        IV78 (71%)
Interval between the first posttreatment PET/CT and completion of chemoradiation (range) (mean) (median) (wk)3–46, 11, 9
Duration of follow-up (range) (mean) (median) (yr)1.3–9.7, 4.9, 4.4
Total patients with residual or recurrent disease within 2 yr after scompletion of primary chemoradiation therapya17/110 (15%)

  • Note:—HPV indicates human papillomavirus; TNM, Tumor, Node, Metastasis.

  • ↵a NPV = 85% (95% CI, 77%–90%).